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Abstract
The paternally expressed gene PEG10 is a retrotransposon derived gene adapted through mammalian evolution located on
human chromosome 7q21. PEG10 codes for at least two proteins, PEG10-RF1 and PEG10-RF1/2, by -1 frameshift translation.
Overexpression or reinduced PEG10 expression was seen in malignancies, like hepatocellular carcinoma or B-cell acute and
chronic lymphocytic leukemia. PEG10 was also shown to promote adipocyte differentiation. Experimental evidence
suggests that the PEG10-RF1 protein is an inhibitor of apoptosis and mediates cell proliferation. Here we present new data
on the genomic organization of PEG10 by identifying the major transcription start site, a new splice variant and report the
cloning and analysis of 1.9 kb of the PEG10 promoter. Furthermore, we show for the first time that PEG10 translation is
initiated at a non-AUG start codon upstream of the previously predicted AUG codon as well as at the AUG codon. The
finding that PEG10 translation is initiated at different sides adds a new aspect to the already interesting feature of PEG10’s
21 frameshift translation mechanism. It is now important to unravel the cellular functions of the PEG10 protein variants and
how they are related to normal or pathological conditions. The generated promoter-reporter constructs can be used for
future studies to investigate how PEG10 expression is regulated. In summary, our study provides new data on the genomic
organization as well as expression and translation of PEG10, a prerequisite in order to study and understand the role of
PEG10 in cancer, embryonic development and normal cell homeostasis.
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Introduction
In 2004, the International Human Genome Sequencing
Consortium published an analysis and annotation of the nearly
completed human genome sequence (,99%) with an estimated
number of 20.000–25.000 protein coding genes [1]. Despite this
surprisingly low number of coding genes the complexity of the
proteome is generated in part by alternative splicing. Alternative
splicing gives rise to a varying number of mRNAs coding for a set
of one to several differentially assembled proteins originating from
one gene. The imprinted human gene ‘‘Paternally Expressed
Gene’’ 10 (PEG10) and its mouse ortholog Peg10/Edr use a
different mechanism coding for more than one protein by 21
ribosomal frameshift translation [2,3], which is well known from
retroviruses and retrotransposons [4]. PEG10 and the human
paraneoplastic antigen gene MA3 [5] are to our knowledge
currently the only two human genes known to use this mechanism.
PEG10 that is thought to be derived from the Ty3/Gypsy family
of retrotransposons [6] has two open reading frames named RF1
and RF2 overlapping by 61 nucleotides. RF1 codes for the gag-like
PEG10-RF1 protein and RF2 codes for a pol-like protein and is
part of the PEG10-RF1/2 fusion protein due to 21 frameshift
translation. PEG10-RF1 contains an N-terminal coiled-coil
domain and a C-terminal zinc finger domain, commonly found
in retroviral gag proteins. In addition, there is a functional aspartic
protease motif in PEG10-RF1/2 shortly after the frameshift site
leading to proteolytic cleavage products of different sizes [2,7]. In
order to perform the 21 frameshift, the RF1-RF2 overlap
sequence contains a seven nucleotide ‘‘slippery’’ sequence with
typical consecutive homopolymeric triplets. The underlined
PEG10 ‘‘slippery’’ heptanucleotide sequence GGGAAACTC follows
the general pattern of X XXY YYZ where the A- and P-site tRNAs
detach from the zero frame codons XXY YYZ and re-pair after
shifting back one nucleotide to XXX YYY (4). Thus, the deduced
amino acid sequence of the frameshift site after frameshift
translation is GNGKL (translated nucleotide sequence: GGA
AAC GGG AAA CTC). The spacer region between the shift site
and the 39 pseudoknot that in addition to the ‘‘slippery’’
heptanucleotide is necessary to promote the 21 frameshift is 5
nucleotides long [8].
PEG10 orthologs were identified in 11 other eutherian species as
well as in the metatherian tammar wallaby (Macropus eugenii)
[7,9,10,11,12]. The heptanucleotide ‘‘slippery’’ sequence is
completely conserved in all species and the sequence of the
downstream pseudoknot is completely conserved in the mamma-
lian species too, except for one nucleotide change in the rodent
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species have retained the ability to translate both PEG10 reading
frames by 21 frameshifting. Within the group of eutherian PEG10
orthologs, mouse and rat Peg10 are the most divergent from the
others and contain small and large insertions within both reading
frames, i.e. a large insertion within the second reading frame of the
mouse gene [2,11].
The adaptation and fixation of a former retrotransposon in the
genome and its high conservation in different mammalian species
argues for an important function of PEG10. Studies with mice
showed a high expression during embryonic development
especially from day 9.5 to 16.5., specifically in bone and cartilage
forming tissues. High expression was also seen in extra embryonic
tissues at all stages between E7.5 and E17.5. Mouse placenta is
positive for Peg10 transcripts as well as the Peg10-RF1 and Peg10-
RF1/2 proteins [7]. Peg10 knock-out mice showed early
embryonic lethality at 10 days post-coitus due to defects in the
placenta [13]. In addition, mouse Peg10 is highly expressed in the
embryo but so far only detected in testis and brain of adult animals
[3]. In humans, high expression of PEG10 in adult tissues was seen
in brain, kidney, lung, testis and weak expression in spleen, liver,
colon, small intestine and muscle [2,9]. PEG10 expression in
human placenta and detection of the corresponding PEG10-RF1
and PEG10-RF1/2 proteins was shown for different gestation
stages [7,14].
PEG10 is not only involved in embryonic development but
PEG10-induced expression was also reported for regenerating
mouse liver [15]. Furthermore, overexpression or reinduced
expression of PEG10 was seen in several malignancies, like
hepatocellular carcinoma [15,16,17], the embryonic kidney
malignancy Wilms tumor (WT) [18], pancreatic cancer [19], B-
cell acute and chronic lymphocytic leukemia (ALL and CLL)
[20,21] and the embryonic form of biliary atresia [22]. It appears
that overexpression of PEG10 leads to an inhibition of apoptosis in
hepatic cancer [16] and B-cell ALL and CLL [20,21], which was
demonstrated by either siRNA mediated knock-down of PEG10
leading to apoptosis or by overexpression of the PEG10-RF1
protein in hepatoma cells rendering resistance to apoptosis and
promoting cell growth [16]. It was further shown, that PEG10
binds to different TGF-b receptors and blocks TGF-b signaling
[2].
The PEG10 gene consists of two exons, separated by a 6.8 kb
intron, giving rise to a ,6.6 kb transcript [2]. Exon 1 contains the
59-UTR and exon 2 contains the RF1 and RF2 coding regions and
a ,4k b 3 9-UTR sequence. PEG10 is located on human
chromosome 7q21 in a head-to-head orientation with the also
paternally expressed sarcoglycan e gene SGCE. Both genes belong
to an imprinted gene cluster in humans as well as in the syntenic
chromosomal regions of several other mammalian species
[23,24,25,26]. Based on the human genome sequence, PEG10
and SGCE are separated by less than 200 bps. Previously, it was
reported that the male hormone androgen promotes PEG10
expression and that the androgen receptor directly interacts in vivo
with androgen-responsive elements in the promoter region and
exon 2 of the PEG10 gene [27]. In a different study it was shown
that c-MYC enhances PEG10 expression in solid cancer and B-cell
lymphoblasts [19]. There are several conflicting data entries
(AB028974, AB049150, AB049834, AF216076, AL589326,
BC050659, BP250746) with various PEG10 59-UTR mRNA
sequence lengths. Thus, the exact transcription start site is
uncertain. Therefore, in line with this, the exact PEG10 promoter
region is not clear either.
In the context of cancer it is important to know how PEG10
expression and translation is regulated and what promoter
regions are involved. One goal of this study was to analyse the
PEG10 promoter region. Firstly, the major transcription start
site (mTSS) was defined as well as the existence of further
upstream located TSSs and secondly, a 2 kb fragment upstream
of the mTSS was cloned. The promoter activities of this 2 kb
sequence as well as smaller fragments were analysed using
luciferase reporter assays and bioinformatics. We also investi-
gated the effect of the PEG10 59-UTR sequence on PEG10
translation and show that PEG10 uses different translation start
sites than the one previously predicted. Furthermore, our
analyses led to the identification of a PEG10 splice product
containing a putative new AUG start codon located in frame
upstream of the previous one.
Results
Identification of the PEG10 Major Transcription Start Site
In order to determine the exact PEG10 transcription start site
(TSS) we performed 59-RACE experiments with RNA from the
hepatoma cell line HepG2, previously reported to express
PEG10 [2,15,16], and the neuroblastoma cell line SH-SY5Y.
PEG10 was shown to be highly expressed in brain [2,9].
Therefore, we speculated that PEG10 might be expressed in
SH-SY5Y cells, which was indeed the case when tested for by
semi-quantitative RT-PCR (data not shown). For the 59-RACE
experiments HepG2 and SH-SY5Y RNA was reverse tran-
scribed with a PEG10-specific primer located approximately
500 bp away from the putative 59-end of the PEG10 transcript,
which was chosen to increase the chance for complete extension
to the 59 -end of the message. The PEG10 59-RACE PCR
products were subsequently cloned into a vector and insert
sequences were analysed by sequencing. All clones that
contained a PEG10 specific insert started with an expected
polymeric run of Gs (complementary sequence of the adapter)
and continued with ACACGCGCTTCAACT… . On the
genomic level, 24–30 nucleotides upstream of this sequence,
there is a typical TATA-box sequence (Figure 1A). We
concluded that this sequence most likely represents the TSS
and numbered the A +1 corresponding to nucleotide position
19519958 of reference sequence NT_007933|Hs7_8090.
The literature and database entries suggest additional TSSs
located further upstream, for example at position 245. Therefore,
we used the 59RACE products in a PCR with PEG10 reverse
primer ABP-R2 (located in exon 2 close to the splice site junction)
and a primer for the 245 position. The subsequent PCR resulted
in amplification products of the expected size for HepG2 as well as
SH-SY5Y cells (Figure 1B). Next, we tested whether there are
PEG10 transcripts starting at even further upstream positions
including 270 and 2173. No products were seen for the PCR
with the –173/ABP-R2 primer pair. PCR with primer pair –70/
ABP-R2 was positive for SH-SY5Y whereas only a very faint band
of the expected size was seen with the HepG2 59RACE template
(Figure 1B).
These results suggest (a) that HepG2 and SH-SY5Y cells use
alternative TSSs from the one predicted in the initial experiment
and (b) that the use and strength of alternative PEG10 TSSs differs
between these two cell types at position 270. Nevertheless, due to
the fact that we used gene-specific 59-RACE products in a semi-
nested PCR approach this might have led to an artificial over
representation of alternative PEG10 transcripts in relation to the
suggested major TSS. Therefore, we tested different cell lines for
PEG10 expression and transcription start sites by semi-quantitative
RT-PCR. Two different primer pairs were used with an identical
reverse primer (ABP-R2) but variable forward primers specific for
PEG10 Molecular Analyses
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analysis the cDNA of various cell lines were employed in the
PCRs.
PEG10 is expressed in the cancer cell lines HepG2, HL-60
(promyelocytic leukaemia-derived cells), LCLC-103H, T47D and
the neuroblastoma-derived SH-SY5Y cells as well as in HEK293
and endothelial cells like primary HUVECs and HMEC-1 cells
(Figure 2A). No expression was detected for the myelogenous
leukemia cells K562 and the colon cancer cell lines SW403 and
SW948. Second, the data show that our identified TSS is indeed
the major TSS since the PCR with the +1 TSS-specific forward
primer produces a strong amplification product for all PEG10
positive cells. Whereas, with the 245 TSS-specific forward
primer less intense PCR products were only seen for HL60 and
T47D cells (Figure 2A) and in addition only very faint or almost
invisible bands were seen for HEK293, and SH-SY5Y differen-
tiated cells. Furthermore, it was observed that the PEG10
expression level between the different cell types varies. PCRs for
the housekeeping gene GAPDH served as a positive control for
the RT reactions and the use of equal amounts of cell line-specific
template RNA (Figure 2B). It is interesting to note that
differentiated SH-SY5Y cells show a stronger expression than
non-differentiated cells. In a separate experiment we followed-up
on this and found that PEG10 expression increases during the
differentiation process (see Materials and Methods, data not
shown).
Variable PEG10 Transcript Length Due to Alternative
Polyadenylation
By Northern Blot analysis it has been shown previously that
PEG10 transcripts of different size exist [2,9]. Therefore, we
isolated the 39-ends of PEG10 transcripts by reverse transcription
of HepG2 and SH-SY5Y total RNA with an Oligo-dT-Clamp
oligonucleotide generating cDNAs starting at the 39-ends of gene
transcripts. The resulting cDNA was used in a PCR with different
39-UTR specific PEG10 forward primers in combination with a
Clamp specific reverse primer (39-RACE). By this approach, in
addition to the major polyadenylated ,6.6 kb transcript,
alternatively polyadenylated transcripts of 2.7 kb and 5.3–5.5 kb
in length were detected. However, none of these transcripts
contained the typical ‘‘AATAAA’’ polyadenylation signal motif at
their 39-end (Figure 3).
Cloning and Analysis of the PEG10 Promoter
In order to identify and analyse the PEG10 promoter, an
approximately 2 kb genomic DNA fragment was amplified from
genomic DNA isolated from peripheral blood mononuclear cells with
primers located according to our TSS results at position –1941 and
position +19. This fragment corresponds to nucleotides 19518017 to
19519976 of reference sequence NT_007933|Hs7_8090. The
putative PEG10 promoter region was cloned upstream of the firefly
luciferase gene into the reporter plasmid pGL2-Basic. Surprisingly,
Figure 1. The PEG10 major transcription start site and alternative start sites. A. Upstream and downstream sequence around the major
transcription start site (mTSS) numbered +1. The positions 245, 270 and 2173 represent binding sites of primers used to analyse whether alternative
TSSs exist located further upstream. In addition, at positions 279 and 2112, a T/G and T/C polymorphism, respectively, was identified (data not
shown). B. Total RNA of the indicated cell lines were reversely transcribed with a PEG10-specific oligonucleotide (KIAA-39INNER) located in exon 2. The
cDNA was then used in a PCR reaction with the PEG10 exon 2-specific reverse primer ABP-R2 (located upstream of KIAA-39INNER) and forward primers
located at the indicated positions in regard of the mTSS (see A.). The ABP-F2 oligonucleotide is located in exon 1 next to the exon1|intron border.
doi:10.1371/journal.pone.0008686.g001
PEG10 Molecular Analyses
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by semi-quantitative RT-PCR. A. Total RNA of the indicated cell lines was reverse transcribed (RT) with a mixture of oligo-dT/hexamer
oligonucleotides. The cDNAs were used in PCR reactions with an identical PEG10-specific reverse primer (KIAA-39INNER) but variable forward primers
specific for transcription start sites at position +1o r245, respectively, resulting in approximately 500 bp products. B. PCRs for the GAPDH gene
served as a positive control for the RT reaction and the use of equal amounts of template RNA. +, PCR with cDNA; 2, PCR with total RNA.
doi:10.1371/journal.pone.0008686.g002
Figure 3. PEG10 polyadenylation. Shown is a schematic view of the 6570 bp long PEG10 transcript with a poly-A tail at its 39-end. Shown is also
the PEG10 mRNA 39-end sequence with the two underlined canonical polyadenylation signal motifs. The arrows and appendant numbers mark the
nucleotide positions of putative alternative polyadenylation sites according to identified PEG10 transcripts. The sequences preceding the
polyadenylated nucleotides do not contain a canonical polyadenylation signal motif.
doi:10.1371/journal.pone.0008686.g003
PEG10 Molecular Analyses
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compared to the human reference sequence (nucleotide position
19519848-19519878) (see Figure 4). Therefore, we went back and
sequenced several more clones containing the insert sequence with no
different result. Because the deleted sequence has a repeat structure,
(CCCCCN)x, we initially assumed that the sequence was deleted due
to bacterial recombination activities. Consequently, we repeated the
promoter fragment cloning obtaining identical results. This suggested
that the deletion is indeed on the genomic level. Nevertheless, we
could not completely exclude the possibility that recombination events
take place in the bacteria despite the use of a recA
2 strain. Therefore,
we amplified this region from HEK293 genomic DNA and from ten
individuals with a European or US-American genetic background.
The sequences were determined directly from the PCR products by
bi-directional analysis. This confirmed the 31 bp deletion. In addition,
we identified 37-bp and 71-bp deletions at nucleotide positions
19519842-19519878 and 19519842-19519912, respectively. HEK293
cells have a homozygous 71 bp deletion whereas most of the
individuals were heterozygous for the 31/37 bp deletions or in one
case for a 31/71 bp deletion. Therefore, in contrast to the rest of the
sequenced promoter region, none of the individual genomic
sequences analysed conform to the human reference sequence at
the investigated position. We named the region with the 31-bp
deletion PEG10 Promoter Variant 1 (PPV1), with the 37-bp deletion
PPV2 and with the 71-bp deletion PPV3. The initially cloned
fragment represents a 1910 bp long PEG10 promoter region
upstream of the TSS. This construct was named PEG10-prom
21910
and served as the template for further shortened PEG10 promoter
constructs (see Figure 5).
Next, we tested the promoter activity of the –1910 bp region
and six additional shorter promoter constructs in HEK293 cells
since HEK293 cells express PEG10 endogenously. Figure 5A
shows a schemetical view of the analysed region. The highest
reporter activity was observed for the PEG10-prom
21007 construct
(Figure 5B and 5C). The lowest activity was always seen for
PEG10-prom
2844 followed by PEG10-prom
2220 and PEG10-
prom
2380. Figure 5B shows the mean of two independent
experiments each performed in triplicate. These results were
obtained under standard medium conditions in the presence of
10% FCS. It was previously reportet that PEG10 expression is up
regulated by serum deprivation [28]. Therefore, we analysed the
promoter activity under low serum conditions by incubating the
cells in the presence of 0.2% FCS for 16 hours. The activity of the
promoter constructs were either unchanged or slightly up
regulated under low serum concentrations with the exception of
PEG10-prom
21007. Serum deprivation led to a slight but
consistent increase in PEG10-prom
21910 reporter activity in all
assays (Figure 5B and 5C). Whereas for PEG10-prom
21007 0.2%
FCS led to increased (Figure 5C) as well as decreased reporter
activity (Figure 5B) compared to 10% serum conditions. In
conclusion, it can be said that the most 59 1 kb of the PEG10
promoter sequence tested shows the highest promoter activity, and
contains a repressor region between 2380 and 2844 and an
enhancer region between 2844 and 21007. Further regulatory
activities can be assigned to the 21007 to 21910 sequence which
showed some promoter repression.
Influence of c-MYC on PEG10 Promoter-Reporter
Activities and Expression
It was previously reported that c-MYC up-regulates PEG10
expression [19]. Thus, we analysed the effect of c-MYC on our
promoter constructs. HEK293 cells were co-transfected witha c-
MYC expression plasmid and different PEG10 promoter con-
structs. Cells were cultured in the presence of 10% or 0.2% FCS
and reporter activity was measured after 16 hours. None of the
tested promoter constructs showed an increased reporter activity
due to c-MYC. Quite the opposite, ectopic c-MYC expression
reduced the promoter reporter activity for all constructs with the
highest effect for PEG10-prom
21007 and PEG10-prom
21910 under
all conditions. Figure 5C shows the mean results of two
independent experiments performed in triplicate. In the previous
report mentioned, the authors investigated their promoter-
reporter constructs in hepatocellular carcinoma cells. In addition,
their reporter contained a putative c-MYC binding element, an E-
box consensus sequence located in the PEG10 intron, considered
to be responsible for increased PEG10 expression by c-MYC,
whereas we analysed the PEG10 promoter activity upstream of the
mTSS in HEK293 cells.
The use of promoter-reporter constructs in analyzing promoter
activity is a legitimate and well excepted method although, only a
defined shortened promoter region for a specific gene becomes
analysed and consequently does not realy reflect the contextual in
vivo situation of gene regulation with further up- or down-stream
located regulatory regions. Therefore, we further analysed c-MYC
regulated PEG10 expression in HEK293 and HepG2 cells by
semi-quantitative RT-PCR (sqRT-PCR). HEK293 and HepG2
cells were transfected with the c-MYC expression construct and
then cultered over night in the presence of 0.2% or 10% FCS in
parallel with non-transfected cells. Subsequently, total RNA was
isolated, reverse transcribed and used for sqRT-PCR with primers
Figure 4. PEG10 promoter variants. The sequence named NCBI 2162 to +2 corresponds to nucleotides 19518795 to 19519959 of reference
sequence NT_007933|Hs7_8090 and represents the PEG10 promoter sequence in regard to the PEG10 mTSS. Analyses of this promoter region
revealed three different PEG10 promoter variants (PPV) named PPV1, 2 and 3. The variants are characterised by 31, 37 and 71 nucleotide deletions as
compared to the reference sequence.
doi:10.1371/journal.pone.0008686.g004
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MYC. For c-MYC two different primer pairs were used with an
identical reverse rimer (c-MYC-rev2) but different forward
primers, c-MYC-fwd2 and c-MYC-fwd. c-MYC-fwd2 binds in
the 59UTR upstream of the ATG and c-MYC-fwd, also used for
expression construct cloning, binds to the ATG start codon region.
Effective transfection of cells with the expression construct was
expected to yield increased PCR product amounts with primer
pair c-MYC-fwd/c-MYC-rev2 in comparison to non-transfected
cells. This was indeed the case as shown in Figure 6. However, it
appears as if there is no enhanced PEG10 expression in the
presence of ectopic c-MYC.
Figure 5. Analysis of PEG10 promoter fragments by promoter-reporter luciferase assays. A. Shown is a schematic view of 1.9 kb of
the PEG10 promoter variant 1 (PPV1). The numbers indicate the 59-end and length in bp of the evaluated promoter regions in (B.) and (C.) in
relation to the transcription start site +1. B. Functional analysis of the PEG10 promoter. PEG10 promoter regions of different length, as indicated,
were cloned upstream of the luciferase gene into the reporter plasmid pGL2-Basic. Equal molar amounts of the different promoter constructs
were transfected into HEK293 cells. Luciferase activity was measured 48h after transfection and an over-night cultivation with either 10% FCS or
0.2% FCS. The data represent the mean of two independent experiments performed in triplicates plus standard deviation and normalized for
transfection efficiency. C. Ectopic c-MYC expression inhibits PEG10 promoter activity. HEK293 cells were co-transfected with a c-myc expression
construct and equal molar amounts of the indicated promoter constructs. Luciferase assays were performed as described for (B.). The activity of
the PEG10-prom
2220 reporter in the presence of 10% FCS was set to one and used as a reference point to calculate the relative activity changes.
The data represent the mean of two independent experiments performed in triplicates plus standard deviation and normalized for transfection
efficiency.
doi:10.1371/journal.pone.0008686.g005
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PEG10 consists of two exons separated by a 6.8 kb intron.
When we performed the 59-RACE experiments in order to
identify the PEG10 transcription start site we used a reverse
primer located in exon 2 which led to products with the exon
1/exon 2 junction sequence. Most of the products represented the
expected and known exon 1/exon 2 sequence TCGCGTG/
AAATAAG referred to as variant 1 or exon 1a/exon 2. However,
several sequenced clones contained additional 11 nucleotides
at the junction leading to the following splice product
TCGCGTGGTGAGTATGCG/AAATAAG referred to as vari-
ant 2 or exon 1b/exon 2. This finding agrees with the GenBank
PEG10 mRNA sequence entry AK299837.1. On the genomic
level the exon 1a|intron 1 splice site sequence is
TCGCGTG|gtgagtatgcg, the exon 1b|intron 1 splice site
sequence is GTGAGTATGCG|gtgaggacgtt and the intron
1|exon 2 splice site sequence is tacag|AAATAA. Figure 7A
shows the variant 1 and variant 2 exon/intron organization
and junction sequence.
In order to analyse how frequent the alternative exon 1b
splicing event occurs, we amplified this region from HepG2 and
Figure 6. No obvious evidence for enhanced PEG10 expression
due to c-MYC. HEK293 and HepG2 cells were transfected with a c-MYC
expression construct and then cultered over night in the presence of
0.2% or 10% FCS in parallel with non-transfected cells. Subsequently,
total RNA was isolated, reverse transcribed and used for sqRT-PCR with
primers specific for G6PD, PEG10, c-MYC (endogenous) and ectopic c-
MYC. For further details see Results.
doi:10.1371/journal.pone.0008686.g006
Figure 7. PEG10 transcript analysis reveals the existence of two splice variants. A. Shown is the sequence around the splice junctions for
the two PEG10 splice variants. A predicted ATG start codon in exon 2 is underlined. The exon 1b transcript represents a rare splice event, which leads
to a new ATG start codon (underlined) in exon 1b. B. In order to estimate the frequency of PEG10 alternative splicing PEG10-specific PCR was done
with cell line HepG2 and SH-SY5Y cDNA using forward and reverse primers located in exon 1 and exon 2 respectively. PCR products were cloned and
transformed into bacteria. 9 colonies were analysed by colony PCR with the ABP-F2/ABP-R2 primer pair that allows to amplify both splice variants.
PCR products were analysed on an agarose gel and variants were distinguished by size: Variant 1 87bp, variant 2 98bp C. PCR with splice variant
specific primers shows that all of the tested cell lines express the exon 1a as well as the exon 1b transcript variants. In order to detect both splice
variants (left half of Figure) or only variant 2 (right half of Figure), PCRs were performed with the following primer combinations, ABP-F2/ABP-R2
(variant 1 and 2) or ABP-F2b/ABP-R2 (variant 2 specific) respectively. +, PCR with cDNA; -, PCR with total RNA.
doi:10.1371/journal.pone.0008686.g007
PEG10 Molecular Analyses
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the PCR products were cloned. Subsequently, the variant 1 or 2
specific insert sequences of 9 randomly picked clones were
determined by PCR using an exon 2 located reverse primer and
an exon 1a-specific forward primer, which allows the amplifi-
cation of both variants with one primer set, leading to size-
specific variant 1 (87 bp) or variant 2 (98 bp) products
(Figure 7B). This analysis revealed the presence of splice variant
2 in three clones out of nine for HepG2 as well as two for SH-
SY5Y suggesting that the exon 1b variant (variant 2) might
occur with a lower frequency than the exon 1a variant (variant
1). Variant 2-specific PCR with HEK293 cDNA and HL60
cDNA, using a primer set with a forward primer specific for the
variant 2 sequence leading to a 87 bp product, demonstrated
that PEG10 alternative splicing is not only restricted to HepG2
and SH-SY5Y cells (Figure 7C, right part). Furthermore, we
identified not only a PEG10 splice variant but the 11 nucleotide
addition includes a putative new translation start site. Splice
variant 2 contains an upstream ATG, which is in frame with the
in previous reports assumed ATG start codon that is located 228
b a s e sd o w n s t r e a mi ne x o n2 .
The Role of the PEG10 59-UTR in Translation
All studies published so far regarding PEG10 protein translation
used expression constructs with the PEG10 RF1 or RF1/2 coding
sequence starting with an ATG located in exon 2. In this context,
we were interested in the effect of the PEG10 59-UTR sequence on
translation. For this purpose, C-terminal His-tagged PEG10-RF1
and PEG10-RF1/2 expression constructs were generated for both
splice variants of the PEG10 59-UTR, named PEG10-RF1a
His
(RF1a
His), PEG10-RF1b
His (RF1b
His), PEG10-RF1a/2
His (RF1a/
2
His) and PEG10-RF1b/2
His (RF1b/2
His). Figure 8A shows a
schematic view of the different PEG10 constructs. These
constructs and the previously described
HisPEG10-RF1 (
HisRF1)
and
HisPEG10-RF1/2 (
HisRF1/2) constructs [2] without the 59-
UTR sequence were transfected into HEK293 and COS-1 cells.
The expressed proteins were detected by Western blot analysis
using an anti-His antibody and PEG10-RF1 specific antibodies
[2]. For Western blot data interpretation it should be kept in mind
that His-epitope tagging increased the molecular weight for all N-
terminal His-tagged PEG10 proteins by about 4 kDa and for all
C-terminal His-tagged PEG10 proteins by about 5 kDa in
comparison to the corresponding endogenous PEG10 proteins.
Figure 8. Analysis of the PEG10 59-UTR in protein translation. A. Schematic presentation of different PEG10 expression constructs.
HisRF1 and
HisRF1/2 represent constructs without the 59-UTR and the PEG10 coding sequence starts at the in previous reports predicted ATG start codon. The star
in the 59-UTR of the RF1b
His and RF1b/2
His constructs represent the location of a putative new ATG start codon. B. HEK293 cells were mock-
transfected or with the indicated PEG10 expression constructs. 48 h after transfection cells were lysed and aliquots of lysates were subjected to SDS-
PAGE (8% gel) under reducing conditions and Western blots (Wb). PEG10 proteins were detected with PEG10-RF1-specific antibodies (SAON1/SAOP2)
or an anti-His antibody. C. COS-1 and HEK293 cells were mock-transfected or with the indicated PEG10 expression constructs. 48 h after transfection
cells were lysed and aliquots of lysates were subjected to SDS-PAGE (8% gel) under reducing conditions and Western blot. Lysates of non-transfected
HepG2 cells were analysed in parallel. PEG10 proteins were detected with PEG10-RF1-specific antibodies (SAOP2 and SAON1) or an anti-His antibody.
The size of the RF1a/2
His expressed PEG10-RF1 protein corresponds to the HepG2 and HEK293 (mock) endogenous PEG10-RF1 protein.
doi:10.1371/journal.pone.0008686.g008
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HisRF1 into HEK293 cells led to the expression
of a PEG10-RF1 specific protein with an expected size of
approximately 50 kDa (Figure 8B). Referred to as the
HisRF1-
specific 50 kDa protein. Surprisingly, in cells expressing RF1a
His,a
prominent PEG10-specific approximately 55 kDa protein, and an
approximately 50 kDa protein, matching the size of the
HisRF1
protein, were detected. The 55 kDa protein is referred to as to be
the RF1a-specific protein. Furthermore, cells with the RF1b
His
construct expressed an approximately 60 kDa protein and in
addition, but less, a protein of about 50 kDa. The relative amounts
of these proteins according to Western blots were lower than those
expressed by
HisRF1 and RF1a
His. All proteins were detected by
an anti-His antibody as well as PEG10-RF1-specific antibodies,
confirming that these proteins are PEG10 specific. In the RF1a
His
and RF1b
His lanes proteins smaller than the 50 kDa proteins were
detected by the anti-His antibody. These proteins might represent
further processed RF1a and RF1b proteins as known for retroviral
gag proteins. The 60 kDa protein for RF1b
His would match the
size of a protein using the new exon 1b AUG start codon for
translation. Translation efficiency however, appears to be less
compared to the other two constructs. The here for the PEG10
proteins determined molecular weights are only rough estimations
and do vary depending on what molecular weight standards were
used (see M&M).
Next, we tested the protein expression for the three different
RF1/2 constructs (with and without the 59-UTR sequence). The
HisRF1/2 construct gave rise to the described RF1 protein product
of 50 kDa, an approximately 105–110 kDa RF1/2 21 frameshift
translation product and a 40 kDa product (PEG10-CNF) as
previously described [2,7]. All three proteins were detected with
anti-His and PEG10-RF1-specific antibodies (Figure 8B). As
shown for RF1a
His and RF1b
His, the presence of the 59-UTR
sequence again changed the translation initiation site (TIS) leading
to higher molecular weight proteins than for the
HisRF1/2
construct. For the RF1a/2
His expression construct only a
55 kDa protein was detected also present for RF1b/2
His in
addition to a more prominent 60 kDa protein. These proteins
were only detected with RF1-specific PEG10 antibodies but not
with an anti-His antibody because only the 21 frameshift products
contain the His-tag at their C-terminus. RF1 proteins or RF1/2
proteolytic cleavage products without the C-terminus lack the
His-tag.
Aside from expressing larger RF1 proteins than the
HisRF1 and
HisRF1/2 constructs, both constructs, RF1a/2
His and RF1b/2
His,
also express larger 21 frameshift proteins of approximately
115 kDa. The RF1a/2 and RF1b/2 proteins were detected with
the anti-His antibody whereas the reactivity with the PEG10-RF1-
specific antibodies varied and appeared to be much weaker.
Additional proteins were detected on anti-His Western blots with
sizes ranging between those of RF1 and RF1/2 proteins. These
proteins were not seen with the PEG10-RF1-specific antibodies
suggesting that these proteins are proteolytic C-terminal cleavage
fragments of RF1a/2
His and RF1b/2
His translation products with
intact His-tags. Western blots with lysates of COS-1 cells
transfected with the different PEG10 expression constructs showed
a similar detection pattern as seen for HEK293 cells (data not
shown).
The Western blot data for the 59-UTR expression constructs
demonstrated that its presence changes translation initiation
suggesting that a TIS exists upstream of the previously assumed
ATG start codon. It appeared as if the 55 kDa protein is the
predominant RF1 translation product for the 59-UTR-RF1a/2
mRNA. We noted that this 55 kDa protein corresponds
approximately in size to a protein detected with the PEG10-
specific antibodies for mock transfected HEK293 cells, which was
not seen for mock transfected COS-1 cells. Thus, we were
wondering if this protein corresponds to the endogenous PEG10-
RF1 translation product since HEK293 cells express PEG10 (see
Figure 2A and 7C) as do so HepG2 cells. Western blot analyses
with the PEG10-RF1-specific SAON1 and SAOP2 antibodies
demonstrated the presence of a protein in RF1a/2
His transfected
HEK293 and COS-1 cells (Figure 8C) that matches the size of the
endogenous PEG10-RF1 protein of non-transfected HepG2 and
HEK293 cells, detected with the PEG10-RF1-specific antibodies
(Figure 8C). The HepG2 and HEK293 endogenous PEG10-RF1
protein is clearly of higher molecular weight than the one
expressed from the
HisRF1/2 construct. However, this
HisRF1
protein corresponds to another protein of approximately 50 kDa
in HepG2 and HEK293 cells, which also reacted specifically with
the PEG10 antibodies. These results strongly suggest the existence
of a preferentially used start codon upstream of the previously
predicted AUG but that in addition, in HepG2 and HEK293 cells
the AUG is used for translation initiation too.
Endogenous PEG10 Protein Translation Starts from a CUG
Codon
In order to identify the new TIS upstream of the previously
one we looked for a new AUG start codon located in frame with
the previous one. However, there is no in-frame AUG triplet in
the 59-UTR sequence suggesting that PEG10 might use a non-
AUG start codon. Utilization of non-AUG codons in mammalian
mRNAs is observed with increasing frequency and the majority
of such non-AUG TISs are CUG codons [29,30,31]. For PEG10
we identified an in-frame CUG codon 102 nucleotides (equiva-
lent to 34 amino acids) upstream of the AUG codon. Thus, we
hypothesized that this CUG is the major start codon for PEG10
translation. In order to proof this hypothesis by experimental
data, the CUG, the AUG and both codon sequences together
were changed by site directed mutagenesis creating three new
expression constructs named PEG10-RF1a/2
mutATG-His, PEG10-
RF1a/2
mutCTG-His and PEG10-RF1a/2
mutATG/CTG-His.
These constructs, as well as the
HisRF1/2, RF1a/2
His and
RF1a
His constructs, were transfected into COS-1 cells. Cell lysates
of transfected cells, mock transfected COS-1 and non-transfected
HEK293 and HepG2 cells were analysed by SDS-PAGE and
Western blot using the anti-His antibody and PEG10-RF1-specific
antibodies. Western blot results are shown in Figure 9 and protein
bands considered to be PEG10-specific are marked by an asterisk.
For HEK293 and HepG2 cells several endogenous PEG10
proteins were detected with the PEG10 antibodies. One protein
slightly above the 55 kDa reference protein, referred to as the
PEG10-specific 55 kDa protein and one below the marker protein,
referred to as the PEG10-specific 50 kDa protein (Figure 9, anti-
PEG10-RF1 blot). This detection pattern was also observed for
RF1a/2
His and RF1a
His. Minor molecular weight differences are
due to the His-tag. As expected, only the 50 kDa protein was seen
for
HisRF1/2, which suggests that the 50 kDa protein represents
the translation product using the AUG codon. More important for
our hypothesis, for cells transfected with RF1a/2
mutATG-His only
the 55 kDa protein (specific for the CUG start codon) was detected
but not the 50 kDa species. Whereas, RF1a/2
mutCTG-His transfec-
tants expressed only the 50 kDa protein (specific for the AUG start
codon). In accordance with these results, neither the 55 nor the
50 kDa proteins were seen for cells transfected with the double
mutant RF1a/2
mutATG/CTG-His. Surprisingly however, a protein of
about 40 kDa reacted specifically with the PEG10 antibodies.
Obviously, the cellular translation machinery found a new TIS
downstream of the mutated CUG and AUG codons. These data
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the AUG leading to PEG10 proteins of different sizes. In addition,
-1 frameshift translation appears to be independent of what TIS is
selected since all mutant constructs expressed an RF1/2 frameshift
product but naturally of different size, which were all detected by
the anti-PEG10 antibody and even more specifically by the anti-
His antibody (Figure 9). Furthermore, for all RF1/2 constructs
(with and without 59-UTR) proteins of about 60–65 kDa were
specifically detected on the anti-His blot most likely representing
PEG10 C-terminal (RF1a/2
His constructs) or N-terminal (
HisRF1/
2 construct) proteolytic cleavage products from the RF1/2
frameshift proteins due to aspartic protease cleavage (see Figure 9
right panel, marked by asterisks). Based on the experience from
several Western blots for PEG10 with anti-His and anti-PEG10
antibodies, proteins that were thought to be derived from PEG10
are marked by asterisks in Figure 9.
PEG10 and SGCE are Co-Expressed in Various Cell Types
The PEG10 and SGCE genes are in a head-to-head orientation
and separated by less than 200 nucleotides. This region would
correspond to the PEG10 2220 promoter region (see Figure 5A).
Therefore we were interested to see whether the expression of
these two genes is co-regulated. For this purpose we looked for the
expression of PEG10 and SGCE in HEK293, HepG2 and SH-
SY5Y cells by sqRT-PCR. The results demonstrate that the two
genes are co-expressed in all three cell lines. However, it appears
that PEG10 has a higher expression in HEK293 and HepG2 cells
but a lower expression in SH-SY5Y cells in comparison with SGCE
(Figure 10).
Discussion
Recent reports suggest that PEG10 has important functions in
cell proliferation, differentiation, apoptosis and the development of
cancer. However, it is not well known how the PEG10 proteins
influence these functions and how PEG10 expression and
translation is regulated. In order to understand the molecular
mechanism of transcription of a gene, it is essential to identify the
corresponding promoter. Determination of the transcription start
site (TSS) is the first step in identifying the promoter. Here, we
determined what we think is the major TSS (mTSS) and also
showed the existence of alternative TSSs (aTSS) further upstream.
This is in agreement with studies reporting that many eukaryotic
genes do not use a single TSS but that transcription can start from
different sites [32]. For example, Suzuki and colleagues analysed
276 human genes and found that the distribution of TSSs is spread
over a region of 61.7 bp on average for genes with and without a
TATA-box [33]. However, for genes with a TATA-box the TSSs
were more tightly clustered. A more recent study performed a
genome-wide analysis of mammalian promoters which confirmed
the presence of aTSSs for the majority of genes and defined classes
of promoters according to the presence and usage of TATA-box,
CCAAT-box, GC-box and CpG islands in the context of TSSs
[34]. Four categories of promoters and TSSs were classified, (i) a
single dominant peak TSS class (SP) with a single dominant TSS,
(ii) a general broad TSS distribution (BR), (iii) a broad TSS
distribution with a dominant TSS (PB) and (iv) bi- or multimodal
TSSs (MU). Based on our data, the PEG10 promoter may belong
to the PB class. Two more criteria speak for the here defined
PEG10 mTSS. First, it is preceded by a TATA-box (100%
consensus sequence) positioned in the ideal distance of 24–30
Figure 9. Endogenous PEG10 proteins use non-AUG translation intiation. In order to test whether PEG10 uses a putative non-AUG start
codon (CUG) different PEG10 expression constructs (PEG10-RF1a/2
mutATG-His, PEG10-RF1a/2
mutCTG-His and PEG10-RF1a/2
mutATG/CTG-His) mutated at the
putative translation initiation sites were transfected into COS-1 cells and cell lysates were analysed by SDS-PAGE (8% gel) and Western blot with
PEG10-RF1-specific antibodies and an anti-His antibody. Lysates of non-transfected HEK293 and HepG2 cells were analysed in parallel for endogenous
PEG10 proteins. Proteins considered to be PEG10-specific are marked by asterisks.
doi:10.1371/journal.pone.0008686.g009
Figure 10. The head-to-head orientated PEG10 and SGCE gene
are co-expressed in different cell lines. PCR with the cDNA of
HEK293, HepG2 and non-differentiated SH-SY5Y cells and gene-specific
primers demonstrates that PEG10 as well as SGCE are co-expressed. +,
PCR with cDNA; 2, PCR with total RNA.
doi:10.1371/journal.pone.0008686.g010
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G.T(21).A(+1).C.A.C.G, conforms closely to the
Py.Py.A(+1).N.T/A.Py.Py sequence of initiator elements
(Inr) [32] in which the initiation site shows the preferred
pyrimidine-purine di-nucleotide [35]. The spacing of the TATA-
box and Inr would allow these two elements to act synergistically,
which is less efficient or neglectable for a distance of more than
30 bp [36]. It is interesting to note, that the sequence of the
TATA-box and Inr element and the spacing of the two is highly
conserved among various species, i.e. human, mouse, bovine and
dog.
We analysed the PEG10 promoter over a region of 2 kb
upstream of the mTSS. Surprisingly, when we sequenced the
PEG10 promoter of 10 unrelated individuals, homozygous and
heterozygous deletions of 31 bp (PEG10 promoter variant 1,
PPV1), 37 bp (PPV2) and 71 bp (PPV3) were detected in
comparison to the NT_007933|Hs7_8090 reference sequence.
These deletions are located 79 bp and 45 bp, respectively,
upstream of the mTSS. The deletions represent a low complexity
sequence of a CCCCCN repeat. Interestingly, the Pan troglodytes
and Macaca mulatta genomic sequences for this region are 100%
identical to the human genome project sequence but a comparison
of the CCCCCN repeat region with other mammalian species did
not show the repeat. Our data suggest that this part of the human
PEG10 promoter due to its repeat structure represents a region of
copy number variation. Unfortunately we were only able to clone
and therefore to analyse the PPV1 promoter. Future studies need
to investigate the possible effect of copy number variations on
PEG10 promoter activity.
The 1.9 kb PPV1 sequence and shorter versions were cloned
into a luciferase reporter and further analysed in HEK293 cells.
These cells show endogenous PEG10 expression and were
therefore considered to be well suited for PEG10 promoter studies.
All constructs showed promoter activities and a strong activity was
especially seen with the proximal 1 kb promoter region. The
lowest promoter activity was seen for the first 844 bp. Higher and
approximately equal activities were measured for the proximal 220
and 380 bp of the PEG10 promoter. The data suggest that positive
and negative regulatory regions are spread along the first 1000 bp
of the PEG10 promoter. Negative regulatory sequences may be
positioned between nucleotides 2380 and 2844 and possible
positive regulatory motifs are located between nucleotides 2844
and 21007 sequences. In addition, further repressor elements
might be located between position 21007 and 21910. In
conclusion, the PEG10 2220 proximal PPV1 promoter is
sufficient to drive PEG10 expression and further upstream located
in cis acting elements modulate PEG10 expression.
It was recently reported that PEG10 expression is up regulated
by serum deprivation (33). Therefore, we also tested the PEG10
promoter under low serum concentrations (0.2% FCS). In general,
the activity of the promoter constructs were either unchanged or
slightly up regulated. In example, serum deprivation led in all
assays to a slight but consistently increased PEG10-prom
21910
reporter activity (Figure 5B and 5C). Whereas the PEG10-
prom
21007 reporter showed in the presence of 0.2% FCS either a
decreased activity compared to 10% serum conditions (Figure 5B)
or a slight increase (Figure 5C) resulting for these experiments in a
more or less net null affect. Furthermore, sqRT-PCR analyses for
serum deprived HEK293 and HepG2 cells also did not reveal
enhanced PEG10 expression (Figure 6). Thus, our data do not
completely agree with the observation that serum deprivation up
regulates PEG10 expression [28]. Nevertheless, in general it can be
said that in our assays serum deprivation does not lead to reduced
promoter activity. This might be in line with reports that PEG10
expression increases under cellular stress suggesting that possible
stress response elements might be located in the PEG10 promoter.
Such putative stress response elements might be remnants of
PEG10’s lost LTR sequence. LTRs do have promoter functions
and are activated upon stress [37]. Increased expression and
probably increased amounts of PEG10 proteins might protect the
cell from cell death under unfavourable conditions. This would
agree with the described anti-apoptotic activity of PEG10-RF1
[16,20,21] and that PEG10-RF1 protected L02 hepatocytes from
apoptosis after serum deprivation [28].
It was reported that the c-MYC protein up-regulates PEG10
expression and that there is a positive correlation between
increased c-MYC and PEG10 expression in various cancers [19].
Therefore, we tested the possible effect of c-MYC on PEG10
expression by co-transfecting a c-MYC expression construct
together with our PEG10 promoter-reporters into HEK293 cells.
Surprisingly, the expression of the c-MYC protein led to an
inhibition of all tested promoter constructs independent of the
selected serum concentrations. In addition, ectopic c-MYC
expression in HEK293 and HepG2 cells did not result increased
PEG10 expression. The reason for these different findings is not
known but one explanation might be that a c-MYC binding
element, a putative E-box sequence located in the PEG10 intron,
was included in the promoter-reporter constructs of this previous
study, whereas we analysed only the PEG10 promoter activity
upstream of the mTSS.
In order to identify putative PEG10-specific transcription factors
and their binding sites in the PEG10 promoter, the PPV1 sequence
was analysed with the Genomatix MatInspector programme. As
expected, the TATA-box was identified as a binding site for the
TATA-binding protein (TBP). Nucleotide positions 261 to 245
were predicted to be a binding site for E2F members, which was
recently experimentally proven [28]. Four more E2F binding sites
were predicted in further upstream regions. An SP1 binding site
was found at postion 2188 to 2203. On the (+) as well as on the
(2) strand, several sequences were identified related to retroviral
regulatory elements like retroviral polyA signals or a lentiviral
TATA upstream element. These might be relicts of PEG10’s
previous retrotransposon nature. In summary, bioinformatic
analysis identified a limitied number of putative transcription
factors (i.e. TBP, E2F, SP1, AP2) with multiple binding sites for
the 1.9 kb PEG10 PPV1 promoter.
In regard of the 2220 proximal PEG10 promoter, it would be
interesting to evaluate if this sequence in a reversed orientation
serves as a promoter for the SGCE gene. The TBP, E2F and SP1
predicted binding sites for the PEG10 proximal promoter were also
predicted for the opposite strand. The PEG10 2220 proximal
promoter represents the region between the head-to-head
orientated PEG10 and SGCE genes. This poses the question
whether PEG10 and SGCE are co-regulated due to their shared
promoter region. We addressed this question briefly by showing
that PEG10 and SGCE are co-expressed in three different cell lines.
The results show that transcription of the two genes at the same
time is not obscured despite the head-to-head orientation and their
overlapping promoter regions. Nevertheless, it appears that among
the three tested cell lines the expression level between the two
genes varies, suggesting that the overlapping PEG10 and SGCE
promoters may be subjected to differential regulation. This is
further substantiated by a previous report showing that PEG10 and
SGCE are differentially regulated at early pregnancy during the
hypoxic phase [14]. In addition, it also might be possible that
antisense transcription for SGCE or PEG10, respectively, could
influence the relative levels of the different sense transcripts in
certain cells or conditions.
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used expression constructs with a coding sequence starting with a
predicted AUG start codon in exon 2. This AUG with its
surrounding sequence CCCAACAUGA adheres closely to the
Kozak sequence, GCCACCAUGG, considered to be optimal as a
translation initiation site (TIS) [38]. Our data suggest that due to
the presence of the PEG10 59-UTR this AUG codon is not
preferentially used as the TIS but that an alternative TIS further
upstream exists. This new TIS must be in-frame with the
previously assumed AUG start codon and therefore with the C-
terminal His-tag, since all products of the C-terminal His-tagged
expression constructs were detected with anti-His or anti-PEG10
antibodies. However, this new TIS must represent a non-AUG
start codon because there is no in-frame AUG triplet upstream of
the previously assumed AUG start codon. Utilization of non-AUG
codons in mammalian mRNAs is observed with increasing
frequency [29,30,31]. The majority of such non-AUG TISs are
CUG codons. The VEGF-A gene might serve as one example
where protein isoforms exist due to translation initiation at an
AUG initiation site but also at an upstream located CUG [30].
Interestingly for PEG10, there is an in-frame CUG codon 102
nucleotides (equivalent to 34 amino acids) upstream of the
predicted AUG start codon. Our experimental data unambi-
giously demonstrate that the defined CUG triplet is indeed used as
a translation initiation site. Western blot analysis for endogenous
PEG10 proteins in HEK293 and HepG2 cells revealed the
existence of several PEG10-specific proteins of different size like
i.e. 115 kDa representing the RF1a/2 21 frameshift product, a
55 kDa protein representing the CUG start site translation
product and a 50 kDa protein representing the AUG translation
start site product. Interestingly, when we tested an expression
construct in which both start sites were mutated we detected a
PEG10-specific protein of about 40 kDa (Figure 9). This strongly
suggests that there is at least one additional site downstream of the
AUG that can be used as a TIS. We do not know whether this
additional TIS is also used under normal cell physiological
conditions. However, on immunoblots with HepG2 and HEK293
cell lysates a protein of about 40 kDa that reacted with the PEG10
antibodies was occasionally present. Furthermore, we identified a
PEG10 splice variant (PEG10-RF1b/2) that contains a new
putative AUG start codon further upstream of the CUG start
site and our experimental data (Figure 8B) suggests that this new
start site is indeed used by the ribosomal translation complex.
Figure 11A shows part of the putative amino acid (aa) sequence for
the PEG10-RF1b/2 protein starting from the new in-frame AUG
translation codon in exon 1b. This protein is 76 aa longer than the
HisRF1 protein, which starts with the previously assumed AUG
start codon in exon 2.
Translation of pig PEG10 (DQ779285) starts 237 nucleotides
upstream of the previously predicted human AUG and the
corresponding 79 amino acids show high similarity (,80%) to the
N-terminal part of human PEG10-RF1b/2. A similar degree of
similarity also exists for bovine PEG10 (Figure 11B). Furthermore,
comparing human PEG10 with PEG10 from other species,
translation of the orthologous proteins starts upstream of the
predicted human AUG. For example, the mouse translation
initiation site is located 120 nucleotides upstream of the predicted
human start codon. In addition, none of the orthologous proteins
contain at the human AUG position a methionine (Figure 11B)
suggesting that the human CUG TIS is the major translation start
site. Thus, depending on what splice variant is expressed and what
TIS is selected the translated PEG10 proteins can be about 40 aa
or more longer than previously thought. The question now is what
function(s) this part of the PEG10 protein might convey?
Further interesting features for PEG10 were identified. The
PEG10 59- and 39-intron sequence conforms to the canonical
consensus splice site sequences GT and AG respectively [39,40]
and the last nucleotide of intron 1 is a consensus G. However, the
exon junction sequence is unusual with two As on the exon 2 site
instead of the more common ag|GN (N=A, C, G or T) junction
motif. mRNA polyadenylation is an essential step for the
maturation of almost all eukaryotic mRNAs. Polyadenylation
Figure 11. Putative amino acid sequence of the PEG10-RF1b/2 protein and comparison of the N-terminal region with orthologous
proteins. A. Shown is the amino acid sequence for the translated PEG10-RF1b/2 protein starting from the putative ATG start codon in exon 1b. The
N-terminal part of the human PEG10-RF1b/2 up to the methionine coded by the previously predicted ATG start codon in exon 2 is in bold. The amino
acid sequence around the 21 frameshift site is underlined. The aspartate protease motif AMIDSGA is in italic and bold. B. A comparison of the N-
terminal part of PEG10 orthologous proteins up to the position corresponding to the human methionine is depicted.
doi:10.1371/journal.pone.0008686.g011
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polyadenylation site is preceded by the canonical polyadenylation
signal (PAS) A(A/U)UAAA [41] of which two are present in the
PEG10 full-length mRNA sequence (see Figure 3). In the
literature, it is reported that the canonical PAS was only found
for about 75% of analysed transcripts and for about 28% to 49%
of genes two or more sites of alternative polyadenylation were
identified [42,43]. Alternative polyadenylation is often observed in
a tissue- or time-specific manner [44]. In this study, PEG10
transcripts of different length were detected derived from oligo-dT
reverse transcribed RNA. This suggests that alternative polyade-
nylation might also occur for PEG10. Variant polyadenylation uses
different PAS motifs instead of the canonical A(A/U)UAAA and
several alternative PAS hexamere sequences have been reported
[42]. We did not find any of those in the shorter PEG10
transcripts. In case PEG10 transcripts are truly subjected to
alternative polyadenylation then future studies have to address the
question whether this influences PEG10 expression, mRNA
stability, mRNA localisation or translation and if it might be
related to disease processes. PEG10 is most likely derived from a
retrotransposon. Therefore, it is interesting to note that non-
conserved poly(A) sites are associated with transposable elements
to a much greater extent than conserved ones and that the 39-end
of genes can be and were dynamically modified by transposable
elements throughout evolution [45].
PEG10 promotes cell proliferation [15,16], blocks cell death
after serum deprivation [28] and disease related expression of
PEG10 inhibits apoptosis [16,20,21]. In addition, to its role in cell
growth, it was shown that PEG10 is expressed in stem cells [46,47]
and thus, may be involved in the subsequently occurring
differentiation processes. For example, Hishida and colleagues
showed that PEG10 promotes the mitotic clonal expansion of
adipocytes necessary for adipocyte differentiation and that siRNA
mediated PEG10 knock-down blocks the early adipocyte differ-
entiation process [48]. We reported here that the retinoic acid-
induced in vitro differentiation of the neuroblastoma cell line SH-
SY5Y leads to a continuous increase of PEG10 expression over a
period of 14 days. Since PEG10 is highly expressed in brain
PEG10 may also play a role in neuronal cell differentiation.
In this study, we determined the PEG10 major TSS, which
allowed us to identify part of the PEG10 promoter and led to the
cloning of different promoter-reporter constructs. These constructs
can now be used for future studies to investigate how PEG10
expression is regulated. The identification of new PEG10 TISs and
that a non-AUG start codon is most likely the major translation
initiation site adds new aspects to the already interesting feature of
PEG10’s –1 frameshift translation mechanism. It is now important
to unravel the cellular functions of the PEG10 protein variants and
how they are related to normal or pathological conditions. In
summary, our study presents new data on the genomic
organization as well as expression and translation of PEG10,a
prerequisite in order to study and understand the role of PEG10 in
cancer, embryonic development and normal cell homeostasis.
Materials and Methods
Cell Lines and Cell Culture
The following cell lines were used in this study, COS-1,
HEK293, HepG2, HL60, HMEC-1, primary HUVECs, K562,
SH-SY5Y, SW403, SW948 and T47D. COS-1, HEK293 and
SW948 cells were grown in DMEM High Glucose (4,5 g/L)
medium with L-Glutamine supplemented with 10% fetal calf
serum (FCS) and 100 units Penicillin/Streptomycin (PAA
Laboratories). HepG2, HL60, K526, LCLC-103H, SW403 and
T47D cells were cultured in RPMI 1640 medium with L-
Glutamine supplemented with 10% FCS. SH-SY5Y cells were
cultured in Ham’s F12/DMEM with L-Glutamine supplemented
with 15% FCS. SH-SY5Y cells were differentiated over a period of
14 days with 10 mM all-trans retinoic acid. In brief, medium was
exchanged 24 hours after seeding for fresh medium containing
retinoc acid. This was repeated every 48 hours. HMEC-1 cells
were maintained in Endothelial Basal Medium with Endothelial
Supplement and 5% FCS. Primary HUVECs were cultured in
M199 containing HEPES (16 mM), heparin (6.4 U/ml), genta-
micin (80 mg/ml), PD-ECGF (20 mg/ml), 10% foetal calf serum
(FCS) and 10% human serum (a kind gift from the Blood Center,
Mannheim, Germany) and 20 mg/ml ECGF. All cell lines were
cultured at 37uC in a 5% CO2 environment. All media and FCS
were obtained from PAA Laboratories.
Sequencing
Sequencing was done on an ABI Prism
TM 310 Genetic
Analyzer (Applied Biosystems) with gene- or vector-specific
primers and the BigDye Terminator v1.1 Cycle Sequencing Mix
(Applied Biosystems) according to the manufacturer’s instructions.
59-RACE
Total RNA was prepared from the cell lines HepG2 and SH-
SY5Y using the SV Total RNA Isolation System (Promega) according
to the manufacturer’s instructions. In order to get the full length
59-end of the PEG10 transcript the 59 RACE System for Rapid
Amplification of cDNA Ends (Version 2.0, Invitrogen) was used
according to the manufacturer’s instructions. In brief, first strand
cDNA was synthesized by the reverse transcriptase SuperScript
TM
II from ,600 ng of total RNA using 2.5 pmol of the PEG10 gene-
specific primer KIAA-39OUTER. After first strand cDNA
synthesis, the mRNA template was removed by treatment with
an RNase mixture of RNase H and RNase T1. Unincorporated
dNTPs, primers, and proteins were removed from cDNA using a
S.N.A.P. column. A homopolymeric tail was then added to the 39-
end of the cDNA using TdT and dCTP. Since the tailing reaction
was performed in a PCR-compatible buffer, the entire contents of
the reaction could be directly used for a subsequent PCR. PCR
amplification was accomplished using Platinum Taq DNA
polymerase (Invitrogen), a nested, PEG10-specific primer, KIAA-
39INNER, and a deoxyinosine-containing anchor primer (AAP)
provided with the system. A dilution of the original PCR was re-
amplified using the AUAP primer (provided with the system) and
PEG10-specific primers KIAA-39INNER or ABP-R2, respectively.
59 RACE products were cloned into the pCR2.1 TA vector
(Invitrogen) for subsequent characterization by restriction digest
and sequencing. Inserts were sequenced with vector-specific T7
primer.
RNA Isolation, Reverse Transcription and RT-PCR
Total RNA of the different cell lines was isolated with
QIAshredder and the RNeasy Kit (Qiagen). For reverse
transcription (RT) of RNA into cDNA, 1 mg of total RNA was
mixed with 2 ml of 10x RT Buffer, 2 ml of dNTP mix (5 mM,
each), 2 ml of oligo-dT primer/random hexamers (50 pmol, each),
2 ml of 5 mM DTT, 1 ml of M-MuLV Reverse Transcriptase
(200 units/ml, New England Biolabs) and added up to a total
volume of 20 ml with RNase-free H2O. For the RT minus control
no M-MuLV Reverse Transcriptase was added. The mix was
inbubated at 37uC for 1 h and enzyme was heat-inactivated at
65uC for 10 min. Afterwards, the volume was filled-up to 50 ml
with RNase-free H2O. Products were stored at 220uC until use.
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indicated PEG10- and GAPDH-specific primers for gene expression
analyses. GAPDH served as the endogenous control gene to allow
for normalisation between different RNA samples. RT-PCR
experiments with subsequent cloning of the PCR products were
carried out in 50 ml volumes using Phusion Polymerase (Finn-
zymes). All RT-PCRs were done in a Techgene cycler (Techne).
Cycle conditions were 45 s at 96uC for initial denaturing followed
by 25 or 30 cycles at 96uC for 30 s, 58–72uC (primer specific
annealing temperature) for 30 s and 72uC for 1 min and a final
extension step at 72uC for 5 min.
Alternative Polyadenylation
For determination of alternative polyadenylation sites the
39RACE method was used. In brief, RNA was reverse transcribed
by using an oligo-dT-Clamp primer (200 pmol). 1 ml cDNA was
used as template in a PCR reaction with PEG10 specific forward
primers in combination with the Clamp reverse primer. Otherwise
the experiment was carried out as described in the preceeding
paragraph. PCR products were subsequently cloned into the
pPCR-Script Amp SK(+) plasmid and insert sequences were
determined by sequencing.
PEG10 Promoter Cloning
According to the major transcription start site determined in
this study, an approximately 2 kb promoter fragment was
amplified from genomic DNA isolated from peripheral blood
mononuclear cells (PBMNC) with Pfu DNA polymerase (Strata-
gene) and primer pair combination
1941PEG10-fwd/
+19PEG10-
rev. The PCR product was cloned into the XhoI/HindIII sites of
the multiple cloning site of the luciferase reporter plasmid pGL2-
basic (Promega). The promoter sequence was analysed by
sequencing. The obtained promoter construct was named
PEG10-prom
21910. Smaller promoter fragments were generated
by PCR using PEG10-prom
21910 as template DNA and the
+19PEG10-rev primer in combination with different forward
primers (
21666PEG10-fwd,
21555PEG10-fwd,
21007PEG10-fwd,
2844PEG10-fwd,
2380PEG10-fwd,
2220PEG10-fwd). The under-
lined nucleotides in the primer sequences (see Table 1) differ from
the template sequence and were changed in order to generate an
XhoI restriction site. The PCR products were cloned into the
XhoI/HindIII sites of the pGL2-basic plasmid resulting in the
following PEG10 promoter reporter constructs: PEG10-
prom
21666, PEG10-prom
21555, PEG10-prom
21007, PEG10-
prom
2844, PEG10-prom
2380 and PEG10-prom
2220.
Expression Constructs and Cloning
For cell-type specific expression and Western blot analysis,
amino terminal or carboxy terminal His-tagged PEG10 expression
constructs and a c-MYC expression construct were cloned.
HisPEG10-RF1 (
HisRF1) and
HisPEG10-RF1/2 (
HisRF1/2) were
previously described [2]. In order to generate PEG10 expression
constructs containing the 59-UTR sequence, the following primer
pairs were used
+1PEG10-fwd/PEG10-RF1-rev and
+1PEG10-
fwd/PEG10-RF1/2-rev, respectively (see Table 1), to amplify the
RF1 or RF1/2 coding sequence plus the 59-UTR from HepG2 or
SH-SY5Y cDNA. The PCR products were cloned into
pcDNA3.1/V5-His-TOPO-TA resulting the following constructs:
PEG10-RF1a
His (RF1a
His), PEG10-RF1b
His (RF1b
His), PEG10-
RF1a/2
His (RF1a/2
His) and PEG10-RF1b/2
His (RF1b/2
His).
RF1b
His and RF1b/2
His represent splice variants (see Results). c-
MYC was amplified with the primer pair c-MYC-fwd/c-MYC-rev
(see Table 1) from a pool of reversely transcribed total RNA
representing different tissues. The c-MYC PCR product was cloned
into pcDNA4/HisMax-TOPO-TA. All PCRs were done with the
Phusion
TM High-Fidelity DNA Polymerase (Finnzymes) and all
constructs were verified by sequencing.
To analyse the sequence around the splice site in more detail,
exon-intron-exon-spanning primers ABP-F2 and ABP-R2 were
used to amplify this region from HepG2 and SH-SY5Y cDNA.
PCR products were subsequently cloned into pCR2.1 (Invitrogen)
by TA-cloning and sequenced. Plasmid DNA from transformed
bacteria were also analysed by PCR using splice site specific
primer pairs ABP-F2/ABP-R2 (regular splicing) and ABP-F2b/
ABP-R2 (alternative splicing).
Site Directed Mutagenesis
In order to analyse the putative PEG10 translation initiation
sites the sequence of the suspected CTG start codon and the
Table 1. List of primers used in this study.
Primer name Primer sequence
GAPDH-fwd 59-ACCACAGTCCATGCCATCAC-39
GAPDH-rev 59-TCCACCACCCTGTTGCTGTA-39
G6PD-fwd 59-GCAAACAGAGTGAGCCCTTC-39
G6PD-rev 59-GGGCAAAGAAGTCCTCCAG-39
Oligo-dT-Clamp 59-GGCGACGCGTCGACTAGTGCGGCCG-dT18N-39
Clamp reverse 59- GGCGACGCGTCGACTAGTGCGGCCG-39
KIAA-39OUTER, 59-GAGCTTCTGCACCTGGCTCTG-39
KIAA-39INNER, 59-GTTGTTGATCTCTTCAGAGAGCTC-39
ABP-F2 59-CAGAGGAGTCCTCGCGTG-39
ABP-F2b 59-CTCGCGTGGTGAGTATGCG-39
ABP-R2 59-GGATGGAGGCCTGGATCC-39
21910PEG10-fwd 59-ctcgagAATTTGACAGCGGTCACCAG-39
21666PEG10-fwd 59-TTGTTTATTCCTCGAGAGGCTCTC-39
21555PEG10-fwd 59-TACTAAAATGTGCTCGAGTTTGCTCT-39
21007PEG10-fwd 59-TCTGGCCTCGAGCCG-39
2844PEG10-fwd 59-TTTTGTGTTCTCGAGCACTATCAAG-39
2380PEG10-fwd 59-GGGACCTCGAGGTCGC-39
2220PEG10-fwd 59-CCGTCCTCGAGTCTCCC-39
2173PEG10-fwd 59-CCTCGGTAATCCCGTACTC-39
270PEG10-fwd 59-GAGCACGCTGGGATTTGG-39
245PEG10-fwd 59-CTCCTCGGTGCAACCTATAT-39
+19PEG10-rev 59-aagcttCCGAAGTTGAAGCGCGTGT-39
+1PEG10-fwd 59-ctcgagACACGCGCTTCAACTTCG-39
PEG10-RF1-rev 59-aagcttAGCGTAGTGACCTCCTGTTCC-39
PEG10-RF1/2-rev 59-aagcttACAGGGTACTGTAAGATGGAGGC-39
PEG10
mutATG-fwd 59-GTGTGTCCCCAATTTGACCGAACGAAG-39
PEG10
mutATG-rev 59-CTTCGTTCGGTCAAATTGGGGACACAC-39
PEG10
mutCTG-fwd 59-CAACCGTCACCTTAGGTCCCGACTG-39
PEG10
mutCTG-rev 59-CAGTCGGGACCTAAGGTGACGGTTG-39
c-MYC-fwd 59-tggaattcATGCCCCTCAACGTTAGCTTC-39
c-MYC-rev 59-cgctcgagTTACGCACAAGAGTTCCGTAG-39
c-MYC-fwd2 59-AGGCTATTCTGCCCATTTGG-39
c-MYC-rev2 59-CCACATACAGTCCTGGATGA-39
SCGE-fwd 59-ATCACATCGGCCCTAGACAG-39
SCGE-rev 59-ACTTCCTGATAGGTGGACAC-39
doi:10.1371/journal.pone.0008686.t001
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RF1a/2
His expression construct by site directed mutagenesis
(Stratagene) according to the manufacturer’s instruction. The
ATG start site was changed using the PEG10
mutATG-fwd/
PEG10
mutATG-rev primer pair. The putative CTG start site was
changed using the PEG10
mutCTG-fwd/PEG10
mutCTG-rev primer
pair. The correct sequence change was verified by sequencing.
Transient Transfections and Western Blots
COS-1 or HEK293 cells were cultured in 6-well plates to 70–
80% confluency. For transfections, 4 ml JetPEI (Polyplus Trans-
fections)/2 mg DNA/well were used according to the manufac-
turer’s instructions. Briefly, cells were transfected either with 2 mg
empty vector (mock) or with equal molar amounts of different
PEG10 expression constructs added up to 2 mg of DNA with
empty vector. Two days post transfection, cells were lysed in
400 ml lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
0.5% NP-40, 50 mM NaF, 1 mM PMSF+Protease Inhibitor
Cocktail (Sigma)] at 4uC for 30 min. Approximately 40 ml of total
cell lysate were separated by SDS-PAGE and blotted onto
nitrocellulose membranes (Machery & Nagel) for immunodetec-
tion with the indicated primary antibodies and IRDyeH secondary
antibodies (Rockland or LI-COR Biosciences) for the OdysseyH
Infrared Imaging System (LI-COR Biosciences). As protein size
standards the following markers from Fermentas Life Sciences
were used, the Prestained Protein Molecular Weight Marker
(#SM0441), the PageRuler
TM Prestained Protein Ladder
(#SM0671) and the PageRuler
TM Plus Prestained Protein Ladder
(#SM1811). It has to be noted that between these three size
markers reference proteins with the same stated molecular weight
(i.e. 55 kDa) show a different migration. This makes the
determination for the precise molecular weights of the here
studied proteins difficult.
Luciferase Assays
Luciferase-based PEG10 promoter assays were performed with
the Steady-Glo System (Promega). HEK293 or HepG2 cells were
seeded into 6-well plates and grown to 80% confluency. Cells were
transiently transfected with equal molar amounts (approximately
2 mg) of the different PEG10 promoter constructs. The next day
cells of one well were split into 8 wells of a 96-well plate. After
complete adherence cells were serum starved for 4 hours.
Subsequently, medium was exchanged and cells were incubated
for 16 hours with 0.2% FCS or 10% FCS. The pEYFP-N1 vector
(Clontech) (100 ng/transfection) was always included to serve as a
control for transfection efficiency. Luciferase activity was mea-
sured with the Lumi-Imager F1
TM (Roche Applied Science). All
experiments were performed in triplicate and repeated at least
twice.
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